Pledge Therapeutics is focused on developing breakthrough medicines through rational design, particularly targeting challenging drug targets that have previously been considered "undruggable." The company has established a portfolio of first-in-class immune-oncology and antiviral assets, aiming to transform treatment paradigms for life-threatening diseases. Their approach emphasizes the discovery of small molecule drugs that not only engage specific targets but also exhibit significant disease-modifying effects. By concentrating on clinically validated targets, Pledge Therapeutics seeks to bring innovative drug candidates closer to clinical application, enhancing their potential for strategic co-development.

The company's discovery platform employs advanced structural biology, biochemistry, and biophysics to design therapeutics that address clinically relevant drug targets. Pledge Therapeutics utilizes a combination of cell and structure-based data alongside information-driven strategies to create a sophisticated drug discovery engine. This rigorous methodology includes solving high-resolution atomic structures of drug-target complexes, which accelerates the discovery process and enhances the likelihood of developing effective treatments. By leveraging these cutting-edge technologies, Pledge Therapeutics aims to revolutionize the standard of care for various diseases.

United States

Pledge Therapeutics efforts have given rise to a constellation of exciting discoveries, spanning from early drug hits to preclinical candidates. Our success is based on the rapid translation of clinical and disease insights into target identification and development of novel drug molecules. At the core of our effort is the integration of structural and biophysical knowledge of disease targets to accelerate the pace and success of drug development.

Pledge Therapeutics

Company Details